Deutsche Bank Keeps Their Buy Rating on Roche Holding AG (RHHVF)

By Ryan Adsit

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Roche Holding AG (RHHVFResearch Report) today and set a price target of CHF425.00. The company’s shares closed last Tuesday at $374.72.

According to, Papadakis is a 3-star analyst with an average return of 1.8% and a 53.5% success rate. Papadakis covers the Healthcare sector, focusing on stocks such as Roche Holding, Grifols SA, and Galapagos.

Currently, the analyst consensus on Roche Holding AG is a Moderate Buy with an average price target of $409.32, representing a 9.5% upside. In a report issued on September 6, Jefferies also maintained a Buy rating on the stock with a CHF415.00 price target.

See today’s analyst top recommended stocks >>

Roche Holding AG’s market cap is currently $320.1B and has a P/E ratio of 19.90. The company has a Price to Book ratio of 19.88.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.